Fulcrum Therapeutics Inc (FULC) - Net Assets
Based on the latest financial reports, Fulcrum Therapeutics Inc (FULC) has net assets worth $198.37 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($214.86 Million) and total liabilities ($16.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Fulcrum Therapeutics Inc liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $198.37 Million |
| % of Total Assets | 92.32% |
| Annual Growth Rate | 110.6% |
| 5-Year Change | 155.34% |
| 10-Year Change | N/A |
| Growth Volatility | 1967.67 |
Fulcrum Therapeutics Inc - Net Assets Trend (2017–2024)
This chart illustrates how Fulcrum Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Also explore Fulcrum Therapeutics Inc balance sheet assets for the complete picture of this company's asset base.
Annual Net Assets for Fulcrum Therapeutics Inc (2017–2024)
The table below shows the annual net assets of Fulcrum Therapeutics Inc from 2017 to 2024. For live valuation and market cap data, see market value of Fulcrum Therapeutics Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $243.03 Million | +3.33% |
| 2023-12-31 | $235.19 Million | +18.22% |
| 2022-12-31 | $198.94 Million | -5.95% |
| 2021-12-31 | $211.54 Million | +122.25% |
| 2020-12-31 | $95.18 Million | +9.21% |
| 2019-12-31 | $87.15 Million | +14.67% |
| 2018-12-31 | $76.00 Million | +5648.87% |
| 2017-12-31 | $1.32 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Fulcrum Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 48386200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $54.00K | 0.02% |
| Other Comprehensive Income | $130.00K | 0.05% |
| Other Components | $762.25 Million | 313.64% |
| Total Equity | $243.03 Million | 100.00% |
Fulcrum Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Fulcrum Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Regal Investment Fund
AU:RF1
|
$485.65 Million |
|
enGene Holdings Inc. Common Stock
NASDAQ:ENGN
|
$485.67 Million |
|
Community Healthcare Trust Inc
NYSE:CHCT
|
$485.72 Million |
|
DONGGUAN R.COMMERC. H YC1
F:857
|
$485.89 Million |
|
Bloomin Brands Inc
NASDAQ:BLMN
|
$485.45 Million |
|
Qingdao Greensum Ecology Co. Ltd.
SHE:300948
|
$485.40 Million |
|
Keck Seng Malaysia Bhd
KLSE:3476
|
$485.33 Million |
|
Sierra Bancorp
NASDAQ:BSRR
|
$485.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Fulcrum Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 235,193,000 to 243,034,000, a change of 7,841,000 (3.3%).
- Net loss of 9,725,000 reduced equity.
- Other comprehensive income increased equity by 266,000.
- Other factors increased equity by 17,300,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.72 Million | -4.0% |
| Other Comprehensive Income | $266.00K | +0.11% |
| Other Changes | $17.30 Million | +7.12% |
| Total Change | $- | 3.33% |
Book Value vs Market Value Analysis
This analysis compares Fulcrum Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.88x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 94.31x to 1.88x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | $0.08 | $7.36 | x |
| 2018-12-31 | $4.49 | $7.36 | x |
| 2019-12-31 | $3.85 | $7.36 | x |
| 2020-12-31 | $3.75 | $7.36 | x |
| 2021-12-31 | $5.98 | $7.36 | x |
| 2022-12-31 | $4.42 | $7.36 | x |
| 2023-12-31 | $3.84 | $7.36 | x |
| 2024-12-31 | $3.92 | $7.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Fulcrum Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -4.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.16%
- • Asset Turnover: 0.31x
- • Equity Multiplier: 1.07x
- Recent ROE (-4.00%) is above the historical average (-260.03%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -1737.07% | 0.00% | 0.00x | 3.28x | $-23.10 Million |
| 2018 | -42.88% | 0.00% | 0.00x | 1.13x | $-40.19 Million |
| 2019 | -90.77% | -10548.40% | 0.01x | 1.27x | $-87.83 Million |
| 2020 | -71.91% | -775.70% | 0.07x | 1.36x | $-77.96 Million |
| 2021 | -37.03% | -408.77% | 0.08x | 1.11x | $-99.49 Million |
| 2022 | -55.23% | -1732.43% | 0.03x | 1.14x | $-129.77 Million |
| 2023 | -41.39% | -3470.05% | 0.01x | 1.10x | $-120.85 Million |
| 2024 | -4.00% | -12.16% | 0.31x | 1.07x | $-34.03 Million |
Industry Comparison
This section compares Fulcrum Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Fulcrum Therapeutics Inc (FULC) | $198.37 Million | -1737.07% | 0.08x | $485.54 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalasse… Read more